CML08

Australasian Leukaemia and Lymphoma Group (ALLG)

David Ross (Institute of Medical and Veterinary Science)

Dataset includes:

• Data for 40 patients with newly diagnosed CML
• Trial followed CML patients, post TKI thereapy, in complete remission. Patients were monitored for disease relapse post initial treatment.
• Dataset includes demographic data, diagnostic, treatment data, outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Cancer therapy (excl. chemotherapy and radiation therapy)

• Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients
• Reverse Transcription with Random Pentadecamer Primers Improves the Detection Limit of a Quantitative PCR Assay for BCR-ABL Transcripts in Chronic Myeloid Leukemia: Implications for Defining Sensitivity in Minimal Residual Disease
• Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
• Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
• BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
• Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
• Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
• Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
• Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
• Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au